Compare Novavax Inc (NVAX) vs WD 40 Company (WDFC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs WD 40 Company — how do they compare? Novavax Inc trades at $8.11 (market cap $1.30B), while WD 40 Company trades at $237.72 (market cap $3.22B). The key difference: WD 40 Company is far larger — about 2.5× Novavax Inc's market cap, and WD 40 Company pays a 1.7% dividend while Novavax Inc pays none. Which is the better fit depends on your goals.
| NVAX | WDFC | |
|---|---|---|
Market Cap | $1.30B | $3.22B |
Sector | Health | Technology |
52-Week High | $11.19 | $264.91 |
52-Week Low | $6.22 | $187.52 |
Enterprise Value | $800.50M | $3.27B |
Dividend Yield | — | 1.7% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $8.08, down 1.64% on the day, with a bearish technical signal but strong recent earnings beats. The company reported $1.12B revenue in 2025 with a net income of $440.30M, though 2026 projections show a return to losses. Analyst consensus is bullish with a $14.00 price target, but negative shareholder equity and cash flow concerns persist.
Outlook remains mixed: strong valuation ratios and analyst support suggest upside potential, but negative cash flows, high liabilities, and projected 2026 losses pose significant risks. Investor sentiment is cautious amid recent stock declines and shareholder dissent highlighted in recent news.
WDFC trades at $239.59, down 2.92% on the day, with a mixed technical picture showing bullish overall signals but bearish moving averages. The company reported strong Q2 2026 earnings of $2.33 per share, beating estimates, and maintains solid profitability with a 13.22% net income margin. Recent news highlights its brand strength and efficient operations, though some analysts see limited upside.
The outlook is balanced: earnings beats and a strong brand provide support, but high valuation multiples (P/E 36.44) and mixed analyst sentiment (71.42% hold rating) suggest cautious optimism. Key risks include margin pressure from input costs and competitive challenges, requiring careful monitoring of future earnings consistency.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About WD 40 Company
WD-40 Company is a global marketing organization dedicated to creating 'positive lasting memories' by developing and selling products that solve maintenance and cleaning problems. Built around the legendary WD-40 Multi-Use Product, the company operates an asset-light business model, focusing on brand management and innovation while utilizing a network of contract manufacturers to deliver solutions across the Americas, EIMEA, and Asia-Pacific.
Read more on WDFC →
